Lanuti et al (43) previously reported that the combinatorial effect of TRAIL and AG490 on T-cell leukemia was characterized by a significant inhibition of STAT3 phosphorylation compared with the controls or TRAIL alone-treated samples (43). The gene discussed is STAT3; the disease is T-cell leukemia.